Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.

"Potential conflicts of interest. A. F. has received honoraria for lectures from AstraZeneca and Pfizer outside the submitted work. A. R. R. reports honoraria for consultation and lectures from Abbvie, Amgen, Pfizer, Galapagos, Novartis, Janssen, Eli-Lilly, Sanofi, UCB and BMS outside the submitted work. The other authors declare that the research was conducted in the absence of any commercial or financial relationship that could be regarded as a potential conflict of interest.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

"Notes: Acknowledgments. Medical writing and editorial assistance were provided by Renee Gordon, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the authors.: Supplement sponsorship. This article appears as part of the supplement “COVID-19 Vaccination in the Immunocompromised Population,” sponsored by Moderna, Inc."